Submitted:
18 June 2025
Posted:
19 June 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
2.1. Materials, Methods, and Ethics Statement
2.2. Study Population
2.3. Statistical Analyses
3. Results
3.1. Patient Characteristics
3.2. Primary and Secondary Outcomes
3.3. Length of Stay and Hospital Charges
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| ACS | acute coronary syndrome |
| AE | adverse events |
| AI | adrenal insufficiency |
| AKI | acute kidney injury |
| aOR | adjusted odds ratio |
| CI | confidence interval |
| LOS | length of stay |
| NRD | Nationwide Readmissions Database |
| TCM | takotsubo cardiomyopathy |
| THC | total hospitalization charges |
| uOR | unadjusted odds ratio |
References
- Krittanawong, C.; Qadeer, Y.K.; Ang, S.P.; Wang, Z.; Alam, M.; Sharma, S.; et al. Incidence and in-hospital mortality among women with acute myocardial infarction with or without SCAD. Curr. Probl. Cardiol. 2025, 50, 102921. [Google Scholar] [CrossRef] [PubMed]
- Heidari, A.; Ghorbani, M.; Hassanzadeh, S.; Rahmanipour, E. A review of the interplay between Takotsubo cardiomyopathy and adrenal insufficiency: Catecholamine surge and glucocorticoid deficiency. Prog. Cardiovasc. Dis. 2024, 87, 18–25. [Google Scholar] [CrossRef] [PubMed]
- Templin, C.; Ghadri, J.R.; Diekmann, J.; Napp, L.C.; Bataiosu, D.R.; Jaguszewski, M.; et al. Clinical features and outcomes of Tako-tsubo (Stress) cardiomyopathy. N. Engl. J. Med. 2015, 373, 929–938. [Google Scholar] [CrossRef] [PubMed]
- Healthcare Cost and Utilization Project. Introduction to the HCUP National Inpatient Sample (NIS). December 2020. Available online: https://hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2020.jsp (accessed on 8 June 2025).
- Elixhauser, A.; McCarthy, E. Clinical Classifications for Health Policy Research, Version 2: Hospital Inpatient Statistics; U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research: Rockville, MD, USA, 1996. [Google Scholar]
- Husebye, E.S.; Anderson, M.S.; Kämpe, O. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 2018, 378, 1132–1141. [Google Scholar] [CrossRef] [PubMed]
- Charmandari, E.; Nicolaides, N.C.; Chrousos, G.P. Adrenal insufficiency. Lancet 2014, 383, 2152–2167. [Google Scholar] [CrossRef] [PubMed]
- Hahner, S.; Allolio, B. Management of adrenal insufficiency in different clinical settings. Expert Opin. Pharmacother. 2005, 6, 2407–2417. [Google Scholar] [CrossRef] [PubMed]
- Bancos, I.; Hazeldine, J.; Chortis, V.; Hampson, P.; Taylor, A.E.; Lord, J.M.; et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. Eur. J. Endocrinol. 2017, 176, 471–480. [Google Scholar] [CrossRef] [PubMed]
- Téblick, A.; Peeters, B.; Langouche, L.; Van Den Berghe, G. Adrenal function and dysfunction in critically ill patients. Nat. Rev. Endocrinol. 2019, 15, 417–427. [Google Scholar] [CrossRef] [PubMed]
- Dalegrave, D.; Silva, R.L.; Becker, M.; Gehrke, L.V.; Friedman, G. Insuficiência adrenal relativa como preditora de gravidade de doença e mortalidade do choque séptico. Rev. Bras. Ter. Intensiva 2012, 24, 362–368. [Google Scholar] [CrossRef] [PubMed]
- Slavin, S.D.; Khera, R.; Zafar, S.Y.; Nasir, K.; Warraich, H.J. Financial burden, distress, and toxicity in cardiovascular disease. Am. Heart J. 2021, 238, 75–84. [Google Scholar] [CrossRef] [PubMed]

| NRD 2019 data |
TCM (N = 30,987) |
|
| Group description |
AI (N = 183) |
No AI (N = 30,804) |
| Characteristic | AI group (n=183) | Non-AI group (n=30,804) | p-value |
|---|---|---|---|
| Sex, % | 0.1 | ||
| Male | 5.9 | 10.0 | |
| Female | 94.1 | 90.0 | |
| Age category (years), % | 0.5 | ||
| 18–34 | 2.9 | 1.6 | |
| 35–65 | 40.2 | 38.5 | |
| >65 | 56.9 | 60.0 | |
| CCI Score, % | 0.0009 | ||
| 0 | 13.9 | 24.8 | |
| 1 | 22.5 | 28.2 | |
| 2 | 17.8 | 21.1 | |
| ≥3 | 45.8 | 26.0 | |
| Median household Income (USD), % | 0.8 | ||
| $1–49,000 | 25.2 | 23.8 | |
| $50,000–64,999 | 22.2 | 27.7 | |
| $65,000–85,999 | 29.6 | 27.2 | |
| ≥$86,000 | 23.0 | 21.3 | |
| Insurance, % | 0.4 | ||
| Medicare | 68.4 | 63.3 | |
| Medicaid | 6.2 | 8.5 | |
| Private | 22.5 | 25.5 | |
| Self-pay | 2.9 | 2.7 | |
| Tobacco use, % | 36.5 | 42.5 | 0.3 |
| Diabetes type 1, % | 1.9 | 0.4 | 0.01 |
| Diabetes type 2, % | 31.0 | 20.0 | 0.02 |
| Heart failure, % | 50.1 | 33.3 | 0.001 |
| Hypothyroidism, % | 30.0 | 19.0 | 0.02 |
| Hyperthyroidism, % | 2.9 | 0.9 | 0.09 |
| Prior AMI, % | 5.7 | 8.5 | 0.4 |
| Prior stroke, % | 8.9 | 6.5 | 0.4 |
| Hypertension, % | 41.0 | 44.0 | 0.6 |
| Dyslipidemia, % | 41.0 | 48.0 | 0.2 |
| Outcome | AI Group (%) | Non-AI group (%) | Unadjusted OR (uOR) | 95% CI | p-value |
|---|---|---|---|---|---|
| In-hospital mortality | 6.1 | 1.6 | 3.91 | 1.77–8.63 | 0.001 |
| Cardiogenic shock | 24.2 | 5.0 | 6.04 | 3.74–9.75 | <0.001 |
| Mechanical ventilation use | 15.9 | 5.0 | 3.57 | 2.05–6.24 | <0.001 |
| AKI | 24.2 | 10.8 | 2.64 | 1.58–4.40 | <0.001 |
| Vasopressor use | 4.6 | 0.8 | 5.56 | 1.98–15.65 | 0.001 |
| 90-day readmissions (all-cause) | 9.3 | 19.4 | 0.43 | 0.24–0.77 | 0.004 |
| Outcome | Adjusted OR (aOR) | 95% CI | p-value |
|---|---|---|---|
| In-hospital mortality | 3.32 | 1.43–7.74 | 0.005 |
| Cardiogenic shock | 5.28 | 3.16–8.82 | <0.001 |
| Mechanical ventilation use | 3.20 | 1.78–5.74 | <0.001 |
| Acute kidney injury (AKI) | 1.96 | 1.11–3.48 | 0.021 |
| Vasopressor use | 4.59 | 1.56–13.47 | 0.006 |
| 90-day readmissions (all-cause) | 0.44 | 0.25–0.79 | 0.006 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).